Reference number
2546-A

Aetna Medicare Part B Drug Criteria

Xolair-Omlyclo

This policy is for Aetna Medicare members. Find the Aetna Commercial Medical Drug Criteria.

For Aetna Medicare members, National Coverage Determinations (NCDs) and Local Coverage Determinations (LCDs) will be applied to Part B drug requests when applicable. Aetna Medicare Part B Drug Criteria documents will be used in the absence of an NCD and LCD.

POLICY

Products Referenced by this Document

Drugs that are listed in the following table include both brand and generic and all dosage forms and strengths unless otherwise stated. Over-the-counter (OTC) products are not included unless otherwise stated.

Brand Name	Generic Name
Xolair	omalizumab
Omlyclo	omalizumab-igec

Indications

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

FDA-approved Indications[1,2]

Allergic Asthma

Xolair and Omlyclo are indicated for moderate to severe persistent asthma in adult and pediatric patients 6 years of age and older with a positive skin test or in vitro reactivity to a perennial aeroallergen and symptoms that are inadequately controlled with inhaled corticosteroids.

Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

Xolair and Omlyclo are indicated for add-on maintenance treatment of chronic rhinosinusitis with nasal polyps in adult patients 18 years of age and older with inadequate response to nasal corticosteroids.

IgE-mediated Food Allergy

Xolair and Omlyclo are indicated for the reduction of allergic reactions (Type 1), including anaphylaxis, that may occur with accidental exposure to one or more foods in adult and pediatric patients aged 1 year and older with IgE-mediated food allergy.

Xolair and Omlyclo are to be used in conjunction with food allergen avoidance.

Chronic Spontaneous Urticaria (CSU)

Xolair and Omlyclo are indicated for chronic spontaneous urticaria in adults and adolescents 12 years of age and older who remain symptomatic despite H1 antihistamine treatment.

Limitations of use

- Not indicated for relief of acute bronchospasm or status asthmaticus
- Not indicated for the emergency treatment of allergic reactions, including anaphylaxis
- Not indicated for other forms of urticaria

Compendial Uses[3,8]

- Prophylaxis of seasonal or perennial allergic rhinitis
- Latex allergy prophylaxis for patients unable to avoid latex
- Adjunct to immunotherapy for seasonal allergic rhinitis
- Immune checkpoint inhibitor-related toxicities
- Systemic mastocytosis

All other indications will be assessed on an individual basis. Submissions for indications other than those listed in this criteria should be accompanied by supporting evidence from Medicare approved compendia.

Documentation

The following documentation must be available, upon request, for all submissions:

Allergic Asthma

Initial requests

- Chart notes or medical record documentation showing pre-treatment IgE level.
- Chart notes, medical record documentation, or claims history supporting previous medications tried including drug, dose, frequency, and duration. If therapy is not advisable, documentation of clinical reason to avoid therapy.

Continuation requests

Chart notes or medical record documentation supporting benefit from therapy.

CRSwNP

Initial requests

- Chart notes or medical record documentation showing nasal endoscopy, anterior rhinoscopy, or computed tomography (CT) details (e.g., location, size), or Meltzer Clinical Score or endoscopic nasal polyp score (NPS) (where applicable).

- Chart notes, medical record documentation, or claims history supporting previous medications tried (if applicable), including response to therapy. If therapy is not advisable, documentation of clinical reason to avoid therapy.

Continuation requests

Chart notes or medical record documentation supporting benefit from therapy.

IgE-Mediated Food Allergy

Initial requests

Chart notes, medical record documentation, or laboratory tests showing the following (if applicable):

- Pre-treatment allergen-specific IgE level
- Skin-prick test wheal diameter
- Pre-treatment serum IgE level
- Positive result of a physician controlled oral food challenge
- History of a life-threatening reaction to a specific food

Continuation requests

Chart notes or medical record documentation supporting benefit from therapy.

CSU

Initial requests

Chart notes, medical record documentation, or claims history supporting previous mediations tried, including response to therapy.

Continuation requests

Chart notes or medical record documentation supporting benefit from therapy.

Immune Checkpoint Inhibiter-Related Toxicity

Initial requests

Chart notes or medical record documentation showing pre-treatment IgE level.

Continuation requests

Chart notes or medical record documentation supporting benefit from therapy.

Systemic Mastocytosis

Initial requests

- Chart notes or medical record documentation supporting diagnosis of systemic mastocytosis.
- Chart notes, medical record documentation, or claims history of prerequisite therapies (if applicable).

Continuation requests

Chart notes or medical record documentation supporting benefit from therapy.

Prophylaxis of Seasonal or Perennial Allergic Rhinitis

Initial requests

Chart notes, medical record documentation, or claims history supporting previous medications tried, including response to therapy.

Continuation requests

Chart notes or medical record documentation supporting benefit from therapy.

Latex Allergy Prophylaxis

Initial requests

Chart notes or medical record documentation of allergy.

Continuation requests:

Chart notes or medical record documentation supporting benefit from therapy.

Adjunct to Immunotherapy for Seasonal Allergic Rhinitis

Initial requests

Chart notes or medical record documentation of immunotherapy use.

Continuation requests

Chart notes or medical record documentation supporting benefit from therapy.

Coverage Criteria

Allergic Asthma[1,2,4,5]

Authorization of 12 months may be granted for treatment of allergic asthma when all of the following criteria are met:

- Member is 6 years of age or older.
- Member has a history of moderate to severe asthma despite current treatment with both of the following medications at optimized doses, unless the member has a clinical reason to avoid these therapies:
  - Inhaled corticosteroid
  - Additional controller (i.e., long-acting beta2-agonist, long-acting muscarinic antagonist, leukotriene modifier, or sustained-release theophylline)
- Member has a positive skin test or in vitro reactivity to at least one perennial aeroallergen.
- Member has a pre-treatment IgE level greater than or equal to 30 IU/mL.
- Member will not use the requested medication concomitantly with other biologics indicated for asthma (e.g., Cinqair, Dupixent, Fasenra, Nucala, Tezspire).

Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)[1,2,12-15]

Authorization of 12 months may be granted for treatment of CRSwNP when all of the following criteria are met:

- Member is 18 years of age or older.
- Member has bilateral nasal polyposis and chronic symptoms of sinusitis despite intranasal corticosteroid treatment for at least 4 weeks unless contraindicated or not tolerated.
- Member has one of the following:
  - A bilateral nasal endoscopy, anterior rhinoscopy, or computed tomography (CT) showing polyps reaching below the lower border of the middle turbinate or beyond in each nostril.
  - Meltzer Clinical Score of 2 or higher in both nostrils.
  - A total endoscopic nasal polyp score (NPS) of at least 5 with a minimum score of 2 for each nostril.
- Member has symptoms of nasal blockage, congestion, or obstruction plus one of the following additional symptoms:
  - Rhinorrhea (anterior/posterior)
  - Reduction or loss of smell
  - Facial pain or pressure
- Member will continue to use a daily intranasal corticosteroid while being treated with the requested medication, unless contraindicated or not tolerated.
- Member will not use the requested medication concomitantly with other biologics indicated for nasal polyps (e.g., Dupixent, Nucala).

IgE-Mediated Food Allergy[1,2,20,21]

Authorization of 12 months may be granted for reduction of IgE-mediated food allergy reactions when all of the following criteria are met:

- Member is 1 year of age or older.
- The diagnosis of IgE-mediated food allergy has been confirmed by either of the following:
  - Pre-treatment food allergen-specific serum IgE level greater than or equal to 6 IU/mL.
  - Skin-prick test (SPC) with wheal diameter greater than or equal to 4 mm.
- Member has either of the following:
  - A positive controlled oral food challenge (e.g., moderate to severe skin, respiratory, or gastrointestinal [GI] symptoms)
  - History of a life-threatening reaction to a specific food
- Member has a pre-treatment serum IgE level greater than or equal to 30 IU/mL.
- Member will continue to follow a food-allergen avoidance diet.

Chronic Spontaneous Urticaria (CSU)[1,2,6,9,10]

Authorization of 12 months may be granted for treatment of CSU when all of the following are met:

- Member is 12 years of age or older.
- Member has experienced a spontaneous onset of wheals (hives), angioedema, or both, for at least 6 weeks.

- Member remains symptomatic despite treatment with a second-generation H1 antihistamine (e.g., cetirizine, fexofenadine, levocetirizine, loratadine) for at least 2 weeks.
- Member has been evaluated for other causes of urticaria, including bradykinin-related angioedema and interleukin-1-associated urticarial syndromes (auto-inflammatory disorders, urticarial vasculitis).

Immune Checkpoint Inhibitor-Related Toxicity[8,22]

Authorization of 12 months may be granted for treatment of immune checkpoint inhibitor-related toxicity when both of the following are met:

- The member has a refractory case of immune-therapy related severe (G3) pruritus with no response to gabapentinoids in one month.
- The member has elevated IgE levels.

Systemic Mastocytosis[8,11]

Authorization of 12 months may be granted for treatment of systemic mastocytosis when both of the following are met:

- The major and at least one minor diagnostic criterion for systemic mastocytosis are present or three or more minor diagnostic criteria are present (see Appendix).
- The requested medication will be used in any of the following treatment settings:
  - Used as stepwise prophylactic treatment for chronic mast cell mediator-related cardiovascular and pulmonary symptoms when the member has tried both of the following:
    - H1 blockers and H2 blockers
    - Corticosteroids
  - Used for prevention of unprovoked anaphylaxis.
  - Used for prevention of hymenoptera or food-induced anaphylaxis, with negative specific IgE or negative skin test.
  - Used improve tolerability of venom immunotherapy.

Prophylaxis of Seasonal or Perennial Allergic Rhinitis[3,7]

Authorization of 12 months may be granted for prophylaxis of seasonal or perennial allergic rhinitis in patients who previously had inadequate symptom control with a combination of intranasal steroids and an intranasal antihistamine.

Latex Allergy Prophylaxis[3]

Authorization of 12 months may be granted for the prophylaxis of latex allergy symptoms in patients with a proven latex allergy and who are unable to avoid occupational latex (e.g., healthcare workers).

Adjunct to Immunotherapy[3]

Authorization of 3 months may be granted as an adjunct to immunotherapy for seasonal allergic rhinitis.

Continuation of Therapy

All members (including new members) requesting authorization for continuation of therapy must be currently receiving therapy with the requested agent.

Authorization of 12 months may be granted when all of the following criteria are met:

- The member is currently receiving therapy with an omalizumab product.
- The requested medication is being used to treat an indication listed in the coverage criteria section.
- The member is receiving benefit from therapy.
- Member will not use the requested medication concomitantly with other biologics indicated for asthma or CRSwNP (e.g., Cinqair, Dupixent, Fasenra, Nucala, Tezspire).

Appendix

2024 WHO Diagnostic Criteria for Systemic Mastocytosis[11]

- Major Criteria: multifocal, dense infiltrates of mast cells (at least 15 mast cells in aggregates) detected in sections of bone marrow and/or other extracutaneous organs
- Minor Criteria
    - Atypical mast cell morphology, including spindle shape or immature morphology, present in greater than 25% of all mast cells on bone marrow smears or in other extracutaneous organ(s).
    - KIT p.D816V mutation or other activating KIT mutation(s) detected in peripheral blood, bone marrow, or other extracutaneous organ(s).
    - Mast cells aberrantly express one or more of the following antigens: CD2, CD25, CD30.
    - Baseline serum tryptase concentration of greater than 20 ng/mL in the absence of an associated myeloid neoplasm; in the case of a known HαT, the tryptase level could be adjusted.

Summary of Evidence

The contents of this policy were created after examining the following resources:

- The prescribing information for Xolair and Omlyclo.
- The available compendium
    - National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium
    - Micromedex DrugDex
    - American Hospital Formulary Service- Drug Information (AHFS-DI)
    - Lexi-Drugs
    - Clinical Pharmacology
- Global Initiative for Asthma (GINA): Global Strategy for Asthma Management and Prevention. 2024 Update.
- Managing asthma in adolescents and adults: 2020 asthma guideline update from the National Asthma Education and Prevention Program
- Clinical Practice Guideline: Allergic Rhinitis

- Joint Task Force on Practice Parameters GRADE guidelines for the medical management of chronic rhinosinusitis with nasal polyposis
- Omalizumab for the Treatment of Multiple Food Allergies
- NCCN Clinical Practice Guidelines in Oncology: Systemic Mastocytosis. Version 1.2025
- NCCN Clinical Practice Guidelines in Oncology: Management of Immune Checkpoint-Related Toxicities. Version 1.2025

After reviewing the information in the above resources, the FDA-approved indications listed in the prescribing information for Xolair and Omlyclo are covered in addition to the following:

- Prophylaxis of seasonal or perennial allergic rhinitis
- Latex allergy prophylaxis for patients unable to avoid latex
- Adjunct to immunotherapy for seasonal allergic rhinitis
- Immune checkpoint inhibitor-related toxicities
- Systemic mastocytosis

Explanation of Rationale

Support for FDA-approved indications can be found in the manufacturer's prescribing information.

Support for using omalizumab for allergic asthma can be found in the manufacturer's prescribing information, the Global Initiative for Asthma (GINA): Global strategy for asthma management and prevention guidelines, and the guideline update from the National Asthma Education and Prevention Program. The prescribing information indicates the minimum labeled age for omalizumab is six years of age. Omalizumab should be used in patients whose symptoms are inadequately controlled with inhaled corticosteroids. According to the 2024 update of the GINA Global Strategy for asthma management and prevention, omalizumab should be considered as an add-on therapy that is uncontrolled on other medications such as long-acting beta2-agonists, leukotriene receptor antagonists, tiotropium, or inhaled corticosteroids-formoterol maintenance and reliever therapy (MART).

The prescribing information for omalizumab as well as the European Forum for Research and Education in Allergy and Airway Diseases (Bachert et al., 2021) support using omalizumab to treat nasal polyps. The prescribing information indicates omalizumab should be used to treat chronic rhinosinusitis with nasal polyps in patients 18 years of age and older with inadequate response to nasal corticosteroids (e.g., mometasone). In the CRSwNP Trial cited in the package insert, patients used nasal mometasone for at least 4 weeks before screening as well as during the treatment period with omalizumab. Prior to randomization, patients were required to have evidence of bilateral polyps as determined by a nasal polyp score (NPS) ≥ 5 with NPS of 2 in each nostril, despite use of nasal mometasone during the run-in period. NPS was measured via endoscopy and scored (range 0-4 per nostril: 0= no polyps; 1=small polyps in the middle meatus not reaching below the inferior border of the middle turbinate; 2=polyps reaching below the lower border of the middle turbinate; 3=large polyps reaching the lower border of the inferior turbinate or polyps medial to the middle turbinate; 4=large polyps causing complete obstruction of the inferior nasal cavity) for a total NPS (range 0-8). Patients were furthermore required to have a weekly average of nasal congestion score (NCS) > 1 prior to randomization, despite use of nasal mometasone. The co-primary endpoints in Trials 1 and 2 were NPS and average daily NCS at Week 24. In both trials, patients who received omalizumab had a statistically significant greater improvement from baseline at Week 24 in NPS and weekly average NCS, than patients who received placebo. The greater improvements in NPS and NCS in the omalizumab group compared to the placebo group were observed as early as the first assessment at Week 4 in both studies cited in the prescribing information. Omalizumab had

statistically significant improvements on sense of smell score compared to placebo. Sense of smell was measured by a daily assessment on a 0 to 3 point severity scale (0=no symptoms, 1=mild symptoms, 2=moderate symptoms, 3=severe symptoms). The least-square mean difference for change from baseline at Week 24 in sense of smell score in omalizumab compared to placebo was -0.3 (95% CI: -0.6, -0.1) in Trial 1 and -0.5 (95% CI: -0.7, -0.2) in Trial 2. omalizumab had statistically significant improvements on post-nasal drip compared to placebo. The least-square mean difference for change from baseline at Week 24 in post-nasal drip score in omalizumab compared to placebo was -0.6 (95% CI: -0.8, -0.3) in Trial 1 and -0.5 (95% CI: -0.8, -0.3) in Trial 2. omalizumab had statistically significant improvements on runny nose compared to placebo. The least-square mean difference for change from baseline at Week 24 in runny nose score in omalizumab compared to placebo was -0.4 (95% CI: -0.7, -0.2) in Trial 1 and -0.6 (95% CI: -0.9, -0.4) in Trial 2.

Support for using omalizumab for the reduction of IgE-mediated food allergy reactions can be found in the manufacturer's prescribing information, and in a double-blind, placebo-controlled trial by Wood et al. (Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen Oral Immunotherapy [OIT] in Food Allergic Children and Adults [OUtMATCH] trial). In the OUtMATCH trial, patients administered omalizumab subcutaneously every 2 to 4 weeks for a total of 16 to 20 weeks, at the doses and frequency based on body weight and total IgE levels. Prior to randomization, patients were required to have history of an allergy to peanut and at least two other foods in the protocol-specified list (cashew, milk, egg, walnut, wheat, and hazelnut). If the results of skin-prick and laboratory testing confirmed the food allergies, double-blind, placebo-controlled oral food challenges followed. A total of 79 of the 118 participants (67%) who received omalizumab were able to consume a single dose of at least 600 mg of peanut protein without dose-limiting symptoms during the post-treatment challenge, as compared with 4 of the 59 participants (6.8%) who received placebo. This phase 3 trial involving patients as young as 1 year of age with multiple food allergies showed that 16 weeks of treatment with omalizumab substantially increased threshold reactivity to peanut and multiple other foods to levels that could protect against allergic reactions associated with accidental exposure.

Support for the above criteria for using omalizumab to treat chronic spontaneous urticaria can be found in the manufacturer's prescribing information, the 2014 guidelines for the diagnosis and management of acute and chronic urticaria (Bernstein et al., 2014), and the EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. The guidelines differentiate between several different causes of urticaria (autoinflammatory disorders, urticarial vasculitis, HAE) and the treatment for these indications differ from the treatment for chronic spontaneous urticaria. Zuberbier et al. (2018) suggest using 2nd generation H1 antihistamines over 1st generation H1 antihistamines for the treatment of chronic urticaria.

Bernstein et al. (2014) indicate patients with episodes of urticaria that last greater than six weeks meet the definition of chronic urticaria. The first step for treating chronic urticaria is monotherapy with second generation antihistamines and avoidance of triggers and relevant physical factors if physical urticaria/angioedema syndrome is present. The second step is dose advancement of the second-generation antihistamine, addition of another antihistamine, addition of an H2-antagonist, addition of a leukotriene antagonist or addition of a 1st generation antihistamine at bedtime. The guideline indicates omalizumab should be used in chronic urticaria refractory to these therapies.

Support for using omalizumab for prophylaxis of season or perennial allergic rhinitis can be found in a multicenter, open-label study by Nayak et al. (2003), conducted during ragweed season, 287 patients (aged 12 to 75) received subcutaneous omalizumab 300 mg every 3 (IgE greater than 150 international units/mL) or 4 weeks (IgE less than or equal to 150 international units/mL) for 12 weeks beginning 2 weeks prior to ragweed season. Chlorpheniramine 4

mg and fexofenadine 60 mg was permitted as rescue medicine. Overall use of rescue medicine in both groups was very low, 84 of 287 (29.3%). At least one adverse event occurred in 47.4% of patients; headache, upper respiratory tract infection and viral infection were most commonly reported. There were no severe adverse events related to omalizumab therapy.

In a phase 3, randomized, double-blind, parallel-group design by Chervinsky et al. (2003), efficacy and safety of subcutaneous omalizumab (minimum dose 0.016 mg/kg/IgE (international units/mL) per 4 weeks) was investigated in 289 patients with moderate-to-severe PAR. All patients had a positive skin prick test, total serum IgE level of 30 to 700 international units/mL, and were chronically exposed to dust mites, dog or cat allergens. Patients ranged from 12 to 75 years of age and had the following relevant comorbid conditions: 26% with history of asthma; 17% with history of atopic dermatitis; 58% with history of intranasal steroid use; 37% had attempted desensitizing immunotherapy. Using a mean daily nasal severity score (range, 0 to 3; mean of 4-point scores for sneezing, itchy, runny, and stuffy nose) as the primary efficacy variable and compared to placebo, omalizumab was associated with larger improvements in symptoms at each of the 4-week visits and for the overall 16-week treatment period (p less than 0.001 for each). In addition, treated patients were more likely to shift to a less severe symptom category compared to the established baseline severity rating (p=0.001); symptoms were considered controlled in 28% of those on active treatment vs 10% of those on placebo. In post hoc analysis in subgroups of patients who had either previously failed desensitization or intranasal steroids, the favorable effects of omalizumab on nasal symptoms persisted. Furthermore, treated patients required antihistamines on statistically significantly fewer days than those on placebo (p=0.005), although the clinical and economic merits of the small reduction may be questioned (maximum difference between the range of days of rescue medication use was 1.2 days per month, and the proportion of rescue days reached statistically significant difference only during week 8). Other secondary measures that showed favorable improvements in the omalizumab group were quality of life measures, including larger differences deemed clinically important, and patients' global evaluation of treatment efficacy. About half of treated patients reported complete control or marked improvement in symptoms, in contrast to that degree of control in only 34% of those on placebo. Omalizumab treatment was well tolerated with the following notable occurrences: 1 patient discontinued the study due to urticaria and 1 patient experienced infectious mononucleosis, although the latter was not attributed to drug therapy. No anti-omalizumab antibodies were detected in patients' sera, and no adverse events suggested drug-induced immunologic reactions.

Support for using omalizumab as latex allergy prophylaxis in healthcare workers exposed to latex on a daily basis can be found in a randomized study conducted by Leynadier and colleagues (2004). Sixteen healthcare workers with documented allergy (positive skin prick test response; elevated Ig E serum levels [30 to 700 international units/mL]) were randomized to receive either placebo or omalizumab subcutaneously every 2 to 4 weeks for 16 weeks, after which all patients could continue or start omalizumab therapy for another 16 weeks. Omalizumab was dosed according to body weight and serum IgE levels and ranged from 150 to 750 mg monthly. Efficacy was measured by mean conjunctival challenge test total score, which is the sum (rated from 0, absent to 3, severe) of physician-evaluated eye redness, eyelid swelling, chemosis, and tearing and patient-rated itching (1, mild to 4, incapacitating). A score of 7 or less is considered normal. Mean score from baseline to week 16 decreased significantly in patients receiving omalizumab compared with placebo (from 10 to 5 vs from 9.67 to 9). Overall ocular response rate after 32 weeks, was 93.8% (15 of 16 patients). Furthermore, 11 of 15 patients had negative response to a latex glove challenge after 32 weeks of treatment, with the remaining 4 having a mild response.

Support for using omalizumab as an adjunct to immunotherapy for seasonal allergic rhinitis can be found in a 4-arm, double-blind, parallel-group, placebo-controlled trial by Casale et al. (2006). The trial found pretreatment with omalizumab significantly decreases the adverse effects associated with rush immunotherapy. Adult patients (n=159;

ages 18 to 50 years) with a minimum 2-year history of ragweed allergic rhinitis and no recent immunotherapy were randomized to receive either immunotherapy and omalizumab, placebo immunotherapy and omalizumab, immunotherapy and placebo omalizumab, or placebo immunotherapy and placebo omalizumab. The dose of omalizumab was 0.016 mg/kg/IgE (international units/mL)/month subcutaneously every 2 to 4 weeks, depending on weight and baseline IgE levels. Rush immunotherapy consisted of ragweed extract in increasing doses up to a maximal dose of 1.2 to 4 mcg Amb a 1 within a 3-hour period, one time. Immunotherapy consisted of weekly short ragweed extract injections in increasing doses over 4 weeks, then 8 weeks of a maintenance dose. Patients in each arm underwent 9 weeks of pretreatment with omalizumab or placebo, followed by rush immunotherapy or placebo. Each arm then underwent 12 weeks in 1 of the 4 treatment arms. Patients that received omalizumab in addition to rush immunotherapy had less adverse effects than patients receiving immunotherapy by itself. In post hoc analysis of the groups receiving rush immunotherapy, the addition of omalizumab was associated with an odds ratio of 0.17 (p=0.026) for anaphylaxis compared to groups not receiving omalizumab. Severity scores during the ragweed season were significantly improved in patients that received both omalizumab and immunotherapy compared to those who received immunotherapy by itself (0.69 vs 0.86; p=0.044).

Support for using omalizumab for systemic mastocytosis can be found in the NCCN's guideline for systemic mastocytosis. The NCCN Guideline for systemic mastocytosis supports the use of omalizumab as a stepwise prophylactic treatment for chronic mast cell mediator-related cardiovascular and pulmonary symptoms. Omalizumab can also be used for the prevention of the following: unprovoked anaphylaxis, hymenoptera or food-induced anaphylaxis with negative specific IgE or negative skin test, or to improve tolerance while on immunotherapy.

Support for using omalizumab for the management of immunotherapy-related toxicities can be found in the NCCN's guideline for management of immunotherapy-related toxicities. The NCCN Guideline supports the use of omalizumab for the management of refractory cases of immunotherapy-related severe (G3) pruritus with increased IgE levels.

References

1. Xolair [package insert]. South San Francisco, CA: Genentech, Inc.; February 2024.
2. Omlyclo [package insert]. Jersey City, NJ: Celltrion USA, Inc.; March 2025.
3. Micromedex (electronic version). IBM Watson Health. Greenwood Village, Colorado, USA. Available at: https://www.micromedexsolutions.com/ (March 1, 2025).
4. Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention. 2024 update. Available at: https://ginasthma.org/wp-content/uploads/2024/05/GINA-2024-Strategy-Report-24_05_22_WMS.pdf. Accessed March 1, 2025.
5. Cloutier MM, Dixon AE, Krishnan JA, et al. Managing asthma in adolescents and adults: 2020 asthma guideline update from the National Asthma Education and Prevention Program. JAMA. 2020;324(22):2301-2317.
6. Maurer M, Rosen K, Hsieh HJ, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med. 2013;368(10):924-935.
7. Seidman MD, Gurgel RK, Lin SY, et al. Clinical Practice Guideline: Allergic Rhinitis. Otolaryngology – Head and Neck Surg. 2015;151(IS):S1-S43.
8. The NCCN Drugs & Biologics Compendium® © 2025 National Comprehensive Cancer Network, Inc. Available at: http://www.nccn.org. Accessed March 1, 2025.
9. Bernstein DI, Blessing-Moore J, Cox L, et al. The diagnosis and management of acute and chronic urticaria: 2014 update. American Academy of Allergy, Asthma & Immunology Practice Parameter.

http://www.aaaai.org/practice-resources/statements-and-practice-parameters/practice-parameter-guidelines.aspx. Accessed March 1, 2025.
10. Zuberbier T, Abdul Latiff AH, Abuzakouk M, et al. The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy. 2022 Mar;77(3):734-766.
11. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Systemic Mastocytosis. Version 1.2025. https://www.nccn.org/professionals/physician_gls/pdf/mastocytosis.pdf. Accessed March 1, 2025.
12. Bachert C, Han JK, Wagenmann M, et al. EUFOREA expert board meeting on uncontrolled severe chronic rhinosinusitis with nasal polyps (CRSwNP) and biologics: Definitions and management. J Allergy Clin Immunol. 2021;147(1):29-36.
13. Fokkens WJ, Lund VJ, Hopkins C, et al. European Position Paper on Rhinosinusitis and Nasal Polyps 2020. Rhinology. 2020;58(Suppl S29):1-464.
14. Hopkins C. Chronic Rhinosinusitis with Nasal Polyps. N Engl J Med. 2019;381(1):55-63.
15. Rank MA, Chu DK, Bognanni A, et al. The Joint Task Force on Practice Parameters GRADE guidelines for the medical management of chronic rhinosinusitis with nasal polyposis. J Allergy Clin Immunol. 2023 Feb;151(2):386-398.
16. Nayak A, Casale T, Miller SD, et al.: Tolerability of retreatment with omalizumab, a recombinant humanized monoclonal anti-IgE antibody, during a second ragweed pollen season in patients with seasonal allergic rhinitis. Allergy Asthma Proc. 2003; 24(5):323-329.
17. Chervinsky P, Casale T, Townley R, et al: Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis. Ann Allergy Asthma Immunol. 2003; 91(2):160-167.
18. Casale TB, Busse WW, Kline JN, et al: Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. J Allergy Clin Immunol. 2006;117(1):134-140.
19. Leynadier F, Doudou O, Gaouar H, et al: Effect of omalizumab in health care workers with occupational latex allergy. J Allergy Clin Immunol. 2004;113(2):360-361.
20. NIAID-Sponsored Expert Panel, Boyce JA, Assa'ad A, et al. Guidelines for the diagnosis and management of food allergy in the United States: report of the NIAID-sponsored expert panel. J Allergy Clin Immunol. 2010;126(6 Suppl):S1-58.
21. Wood RA, Togias A, Sicherer SH, et al. Omalizumab for the Treatment of Multiple Food Allergies. N Engl J Med. 2024;390(10):889-899.
22. NCCN Clinical Practice Guidelines in Oncology® (NCCN Guidelines®). Management of Immune Checkpoint-Related Toxicities. Version 1.2025. Available at: www.nccn.org. Accessed March 1, 2025.

CPT Codes / HCPCS Codes / ICD-10 Codes

Code	Description
CPT codes related to the Med B drug criteria:	
96401	Chemotherapy administration, subcutaneous or intramuscular; non-hormonal anti-neoplastic

HCPCS codes covered if selection criteria are met:	
J2357	Injection, omalizumab, 5 mg
Q5154	Injection, omalizumab-igec (omlyclo), biosimilar, 5 mg
Other HCPCS codes related to the Med B drug criteria:	
Gabapentinoids - No Specific code	
J7622	Beclomethasone, inhalation solution, compounded product, administered through DME, unit dose form, per milligram
J7626	Budesonide, inhalation solution, FDA-approved final product, noncompounded, administered through DME, unit dose form, up to 0.5 mg
J7627	Budesonide, inhalation solution, compounded product, administered through DME, unit dose form, up to 0.5 mg
J7633	Budesonide, inhalation solution, FDA-approved final product, noncompounded, administered through DME, concentrated form, per 0.25 mg
J7634	Budesonide, inhalation solution, compounded product, administered through DME, concentrated form, per 0.25 mg
J7635	Atropine, inhalation solution, compounded product, administered through dme, concentrated form, per milligram
J7636	Atropine, inhalation solution, compounded product, administered through dme, unit dose form, per milligram
J7640	Formoterol, inhalation solution, compounded product, administered through DME, unit dose form, 12 mcg
J7641	Flunisolide, inhalation solution, compounded product, administered through DME, unit dose form, per mg
J7644	Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram
J7645	Ipratropium bromide, inhalation solution, compounded product, administered through dme, unit dose form, per milligram
ICD-10 codes covered if selection criteria are met:	

D47.02	Systemic mastocytosis
D89.40 – D89.49	Mast cell activation syndrome and related disorders
J30.2	Other seasonal allergic rhinitis
J32.0 – J32.9	Chronic sinusitis
J33.0 - J33.9	Nasal polyps
J45.40	Moderate persistent asthma, uncomplicated
J45.50	Severe persistent asthma, uncomplicated
J45.998	Other asthma [allergic asthma]
L25.4	Unspecified contact dermatitis due to food in contact with skin [IgE-mediated food allergy reactions]
L27.2	Dermatitis due to ingested food [IgE-mediated food allergy reactions]
L50.8	Other urticaria [chronic spontaneous]
T45.1X5A - T45.1X5S	Adverse effect of antineoplastic and immunosuppressive drugs [Immune checkpoint inhibitor-related toxicity]
T78.00XA - T78.09XS	Anaphylactic reaction due to food [IgE-mediated food allergy reactions]
T78.1XXA - T78.1XXS	Other adverse food reactions, not elsewhere classified [IgE-mediated food allergy reactions]
Z91.010 – Z91.02	Food allergy status
Z91.040	Latex allergy status

Revision History

Date	Version	Update	Revisions
01/01/2024	2023	New Criteria	Policy effective.

10/01/2024	2023a	Criteria Change	Added new FDA approved indication, IgE-mediated food allergy.
02/01/2025	2024	Criteria Change	For the indication of IgE-mediated food allergy, updated the initial duration of approval to 12 months (previously 6 months). For the indication of immune checkpoint inhibitor toxicity, updated the initial duration of approval to 6 months (previously 1 month).
11/01/2025	2025	Criteria Change	Added newly FDA-approved Omlyclo to the program. For chronic rhinosinusitis with nasal polyps initial criteria, updated intranasal corticosteroid treatment step from 2 months to at least 4 weeks. For Immune checkpoint inhibitor-related toxicity initial criteria, updated approval duration from 6 months to 12 months and if no response to gabapentinoids in one month per NCCN update.

See Evidence of Coverage for a complete description of plan benefits, exclusions, limitations and conditions of coverage. Plan features and availability may vary by service area.